TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Yesterday

Hidden Gems article.

TMFBiologyFool published an update. 4:36 PM

NL

Article

TMFBiologyFool published an article 3:24 PM

Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway

Instead of Tysabri, it's Tecfidera this time.

NL

Article

TMFBiologyFool published an article 1:12 PM

Natus Medical Inc. Hears Higher Margins Calling

Revenue growth was only 5% but improving margins helped increase non-GAAP net income by 16.5%.

Rule Breakers article.

TMFBiologyFool published an update. 11:31 AM

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Tue Oct 21

NL

Article

TMFBiologyFool published an article 8:12 PM

Intuitive Surgical Inc.'s Margins Go Under the Knife

Gross margin slips 200 basis points quarter over quarter, though mostly from temporary issues.

NL

Article

TMFBiologyFool published an article 3:45 PM

Celgene Corporation's Earnings Preview: Pay Attention to New Kids

Revlimid might be the flagship, but growth will come from the newer drugs.

Mon Oct 20

Rule Breakers article.

TMFBiologyFool published an update. 3:59 PM

NL

Article

TMFBiologyFool published an article 2:32 PM

MannKind Corporation's Investors Shouldn't Dance Around This Issue

It's not a good sign that MannKind's competitor can't IPO.

NL

Article

TMFBiologyFool published an article 12:11 PM

3 Ways Intuitive Surgical Inc. Can Slice Up a Solid Third Quarter

Investors should keep an eye on procedure volume, which procedures are being performed, and adoption of the new Xi system.

Thu Oct 16

NL

Article

TMFBiologyFool published an article 4:54 PM

AbbVie Inc to Shire: It's Not You, It's My Country

AbbVie's board recommends that the company not purchase Shire.

Tue Oct 14

NL

Article

TMFBiologyFool published an article 4:22 PM

FDA Sends Mixed Message On Safety of Pfizer inc.'s Chantix

The smoking cessation product might not cause neuropsychiatric events, but the FDA wants more data.

NL

Article

TMFBiologyFool published an article 1:15 PM

Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg

Bristol-Myers Squibb's Opdivo and Merck's Keytruda are sought after drugs for combination cancer treatments.

Fri Oct 10

NL

Article

TMFBiologyFool published an article 4:10 PM

Gilead Sciences Inc. Gets First Hepatitis C Cocktail Drug Approved

Now the question is how much is Gilead Sciences going to make off Harvoni.

Thu Oct 9

NL

Article

TMFBiologyFool published an article 5:40 PM

Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery

Amgen is developing a biosimilar of AbbVie's Humira.

Tue Oct 7

NL

Article

TMFBiologyFool published an article 3:10 PM

Bristol-Myers Co Regroups; Hepatitis C Fight With Gilead Sciences Not Over

Bristol-Myers Squibb pulls its FDA application for daclatasvir and asunaprevir. Here are two possible reasons why.

Mon Oct 6

NL

Article

TMFBiologyFool published an article 2:27 PM

Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?

Esperion Therapeutics might be small, but it could pack a mighty punch.

Fri Oct 3

NL

Article

TMFBiologyFool published an article 2:51 PM

Gilead Sciences, Inc. Got 2 Drugs Approved, and Didn't Bother to Tell Anyone

Gilead Science's Tybost and Vitekta are already part of its approved quad pill Stribild.

Tue Sep 30

NL

Article

TMFBiologyFool published an article 3:32 PM

The Next Blue-Chip Stocks: Biogen Idec

Biogen Idec could hit blue chip status, but it's going to take a few years.

NL

Article

TMFBiologyFool published an article 9:05 AM

Big News for These 5 Stocks From ESMO

But smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.79
Player Rank 2407 out of 75060
Score 1387.53
Score Change Today +46.36
Accuracy 65.38%
Active Picks 73
Total Picks 213
Best Pick MYL (+270.87)
Worst Pick ITMN (-435.78)
Average Score per Pick 6.51
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts